Opinion|Videos|May 8, 2024
Clinical Evidence for Emerging PAH Therapies
Dr Oudiz discusses clinical data that support the efficacy and safety of emerging PAH therapies and ongoing research in the treatment space.
Advertisement
Episodes in this series
Video content above is prompted by the following questions:
- What clinical data support the efficacy and safety of these new treatments, and how do they compare to existing therapies?
- Are there any ongoing clinical trials evaluating promising investigational agents or combination therapies for pulmonary arterial hypertension (PAH)?
Advertisement
Related to this article
The FDA approved asundexian (Sunharbo) with antiplatelet therapy to reduce recurrent stroke risk after noncardioembolic stroke or high-risk TIA.
The FDA granted accelerated approval to amivantamab and hyaluronidase for previously treated recurrent or metastatic head and neck cancer.
A systematic review and meta-analysis found GLP-1 RAs improved liver and metabolic markers in MASLD and MASH, but long-term benefits remain unproven.
Mailed fecal immunochemical test (FIT) outreach raised CRC screening at federally qualified health centers, but gains faded by year 3.
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves Asundexian, First FXIa Inhibitor to Prevent Repeat Stroke
2
How Plans, Clinicians Should Handle Gray-Market Retatrutide
3
IVF Beats IUI for Early Live Births in Unexplained Infertility
4
Phase 3 Data Back ALP Normalization as Treatment Goal in PBC
5